Efficacy and safety of cisplatin plus capecitabine for patients with metastatic triple negative breast cancer progressing after anthracycline and taxane treatment.
- Author:
Qiao LI
1
;
Binghe XU
2
;
Email: XUBINGHE@MEDMAIL.COM.CN.
;
Qing LI
1
;
Pin ZHANG
1
;
Peng YUAN
1
;
Jiayu WANG
1
;
Fei MA
1
;
Yang LUO
1
;
Ying FAN
1
;
Ruigang CAI
1
Author Information
- Publication Type:Journal Article
- MeSH: Anthracyclines; administration & dosage; Antibiotics, Antineoplastic; administration & dosage; Antineoplastic Combined Chemotherapy Protocols; adverse effects; therapeutic use; Bridged-Ring Compounds; administration & dosage; Capecitabine; administration & dosage; adverse effects; Cisplatin; administration & dosage; adverse effects; Disease-Free Survival; Female; Hand-Foot Syndrome; Humans; Leukopenia; chemically induced; Neutropenia; chemically induced; Prospective Studies; Taxoids; administration & dosage; Treatment Outcome; Triple Negative Breast Neoplasms; drug therapy; pathology
- From: Chinese Journal of Oncology 2015;37(12):938-941
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the efficacy and safety of cisplatin and capecitabine combination (XP) therapy for patients with metastatic triple negative breast cancer (TNBC) progressing after anthracycline and taxane treatment.
METHODSTwenty-nine metastatic TNBC patients were prospectively enrolled to receive capecitabine (1, 000 mg/m(2) twice daily on days 1-14) and cisplatin (75 mg/m(2) on day 1) , repeated every 3 weeks.
RESULTSWith a median of 6 cycles of XP, all 29 patients were evaluable for response, including 18 PR (62.1%), 6 SD (20.7%), 5 PD (17.2%) and no CR. The response rate was 62.1%. Patients with earlier stage at diagnosis (stage I to IIIA), longer post-operative disease free survival (>2 years) and less metastatic sites (≤ 3) obtained significantly higher response rate than patients with later stage at diagnosis (stage IIIB to IV), shorter post-operative disease free survival (≤ 2 years) and more metastatic sites (>3). The leading side effects were grade 1/2 gastrointestinal and hematological toxicities. Grade 3/4 toxicities included neutropenia (34.5%), leukocytopenia (31.0%), anemia (6.9%), thrombocytopenia (3.4%), nausea/vomiting (20.7%), stomatitis (3.4%), and hand-foot syndrome (3.4%).
CONCLUSIONCisplatin and capecitabine combination therapy is an active and well-tolerated doublet treatment in metastatic TNBC patients progressing after anthracycline and taxane treatments.
